Rivaroxaban for prevention and treatment of venous thromboembolism

被引：9
|
作者：
Chan, Noel C. [1 ,2 ]
Weitz, Jeffrey, I [1 ,2 ]
机构：
[1] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
FUTURE CARDIOLOGY | 2019年 / 15卷 / 02期
关键词：
nonvitamin K oral antagonist; rivaroxaban; venous thromboembolism; FACTOR-XA INHIBITOR; DIRECT ORAL ANTICOAGULANTS; DEEP-VEIN THROMBOSIS; TOTAL HIP; ORTHOPEDIC-SURGERY; EXTENDED TREATMENT; KNEE REPLACEMENT; REAL-WORLD; ENOXAPARIN; THROMBOPROPHYLAXIS;
D O I：
10.2217/fca-2018-0076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
引用
收藏
页码：63 / 77
页数：15
相关论文
共 50 条
  • [1] Rivaroxaban for the prevention and treatment of venous thromboembolism
    Turpie, Alexander G. G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 (01) : 33 - 38
  • [2] Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach
    Arcelus, Juan I.
    Domenech, Pere
    del Carmen Fernandez-Capitan, Ma
    Guijarro, Ricardo
    Jimenez, David
    Jimenez, Sonia
    Lozano, Francisco S.
    Monreal, Manel
    Nieto, Jose A.
    Paramo, Jose A.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (04) : 297 - 308
  • [3] New Anticoagulants for Prevention and Treatment of Venous Thromboembolism
    Roberts, Lara N.
    Arya, Roopen
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (03) : 373 - 382
  • [4] Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
    Antonijevic, Nebojsa
    Kanjuh, Vladimir
    Zivkovic, Ivana
    Jovanovic, Ljubica
    Vukcevic, Miodrag
    Apostolovic, Milan
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2020, 148 (9-10) : 613 - 620
  • [5] Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism
    Imberti, Davide
    Benedetti, Raffaella
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (04) : 309 - 318
  • [6] Rivaroxaban for the treatment of venous thromboembolism in pediatric patients
    Cohen, Omri
    Levy-Mendelovich, Sarina
    Ageno, Walter
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (11) : 733 - 741
  • [7] A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement
    Song Turun
    Liao Banghua
    Yin Yuan
    Li Zhenhui
    Nie Ying
    Chen Jin
    THROMBOSIS RESEARCH, 2011, 127 (06) : 525 - 534
  • [8] Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison
    Loke, Y. K.
    Kwok, C. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (01) : 111 - 124
  • [9] Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
    Turpie, Alexander G. G.
    Lassen, Michael Rud
    Eriksson, Bengt I.
    Gent, Michael
    Berkowitz, Scott D.
    Misselwitz, Frank
    Bandel, Tiemo J.
    Homering, Martin
    Westermeier, Torsten
    Kakkar, Ajay K.
    THROMBOSIS AND HAEMOSTASIS, 2011, 105 (03) : 444 - 453
  • [10] Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty A meta-analysis
    Huang, Hai-Feng
    Li, Shan-Shan
    Yang, Xian-Teng
    Xie, Quan
    Tian, Xiao-Bin
    MEDICINE, 2018, 97 (48)
12345